Table 3

Adverse events with fatal outcome (n=1587)

Patient 1Patient 2Patient 3Patient 4Patient 5Patient 6Patient 7
Fibrosis stageF4F4F4F3F4F4F4
BSL VL1 200 0002 387 203389 3403 180 0001 430 000977 1002 502 935
Last obs. VLUndetectableUndetectable20570Undetectable
Dates of TVR treatmentJuly 2011 to September 2011December 2011 to February 2012January 2012 to April 2012September 2011 to December 2011November 2011 to February 2012May 2012 to July 2012April 2012 to July 2012
Date of death4 weeks after TVR d/c2 weeks after TVR d/c4 weeks after TVR d/c30 weeks after TVR d/c4 weeks after TVR d/c24 weeks after TVR d/c8 weeks after TVR d/c
Adverse eventAnaemia, dehydration, hepatic failure, hepatorenal syndrome, hyper-catabolism, keto-acidosis, multi-organ failureIschaemic colitis, septic shock, multi-organ failureHepatic failure, bone marrow failure, multi-organ failureAnaemia, hepatic neoplasm malignant, intra-abdominal haemorrhage, pneumoniaAnaemia, oesophageal variceal haemorrhageDiarrhoea, vomit, hypotension, septic shock, comaAnaemia, fatigue, pneumonia
CausalityPossibly relatedRelatedUnlikely relatedUnlikely/not relatedUnlikely relatedNot relatedUnlikely related
Medical historyDiabetesLow platelets (74 000)Neutropenia (830 cells/mm3)
  • BSL, baseline; d/c, discontinued; TVR, telaprevir; VR, viral load.